| Aug 12 |
Atossa Therapeutics GAAP EPS of -$0.05 in-line
|
| Aug 12 |
Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
|
| Aug 10 |
Here's Why We're Not Too Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Situation
|
| Jul 22 |
Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer
|
| Jul 11 |
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?
|
| Jul 3 |
3 Penny Stock Moonshots with 300%+ Upside Potential by 2025
|
| Jul 2 |
Atossa Therapeutics appoints Heather Rees as chief financial officer
|
| Jul 2 |
Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer
|
| Jun 28 |
Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
|
| Jun 25 |
Are Medical Stocks Lagging Alvotech (ALVO) This Year?
|
